Research programme: Filovirus immunotherapeutics - GeoVax Labs

Drug Profile

Research programme: Filovirus immunotherapeutics - GeoVax Labs

Alternative Names: GOVX E301; GOVX E302; GOVX-E303; Haemorrhagic fever vaccine - GeoVax; Monovalent vaccine - GeoVax; MVA-VLP Ebola vaccine - GeoVax; MVA-VLP tetravalent vaccine - GeoVax

Latest Information Update: 08 Aug 2016

Price : $50

At a glance

  • Originator GeoVax Labs
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Ebola virus infections; Lassa fever
  • Research Marburg virus disease

Most Recent Events

  • 01 Jul 2016 Preclinical trials in Lassa fever (Prevention) in USA (Parenteral) before July 2016
  • 29 Feb 2016 GeoVax Labs collaborates with the United States Army Medical Research Institute of Infectious Diseases to develop Filovirus vaccines in USA
  • 20 Apr 2015 GeoVax Labs collaborates with the National Institute of Allergy and Infectious Diseases for development of Filovirus vaccines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top